Stoke Therapeutics, Inc. Payments to Acquire Marketable Securities
Stoke Therapeutics, Inc. (STOK) reported Payments to Acquire Marketable Securities of $45.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-03
- Stoke Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $36.11M, a 80.11% decline year-over-year.
- Stoke Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $9.85M, a 48.19% decline year-over-year.
- Stoke Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $98.23M, a 237.10% increase year-over-year.
- Stoke Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $23.93M, a 52.06% decline year-over-year.
- Stoke Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $322.72M, a 92.93% increase from fiscal 2024.
- Stoke Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $167.27M.
- Stoke Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Stoke Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $201.32M, a 130.80% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $36.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $45.96M 10-Q · filed 2026-08-03 | $144.19M derived: sum of 3 quarters · filed 2026-08-03 | $168.11M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $9.85M 10-Q · filed 2026-05-07 | $108.08M derived: sum of 2 quarters · filed 2026-05-07 | $132.01M derived: sum of 3 quarters · filed 2026-05-07 | $313.56M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $98.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $122.15M derived: sum of 2 quarters · filed 2026-03-16 | $303.71M derived: sum of 3 quarters · filed 2026-08-03 | $322.72M 10-K · filed 2026-03-16 |
| 2025-09-30 | $23.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $205.48M derived: sum of 2 quarters · filed 2026-08-03 | $224.49M 10-Q · filed 2025-11-04 | $253.63M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $181.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $200.57M 10-Q · filed 2026-08-03 | $229.71M derived: sum of 3 quarters · filed 2026-08-03 | $279.61M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $19.02M 10-Q · filed 2026-05-07 | $48.16M derived: sum of 2 quarters · filed 2026-05-07 | $98.06M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $29.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $79.04M derived: sum of 2 quarters · filed 2026-03-16 | $167.27M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $49.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $138.13M 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $88.23M 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | $0.00 10-K · filed 2024-03-25 | |||
| 2022-12-31 | -$4.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $4.84M derived: sum of 2 quarters · filed 2024-03-25 | $57.38M derived: sum of 3 quarters · filed 2024-03-25 | $201.32M 10-K · filed 2024-03-25 |
| 2022-09-30 | $9.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $62.25M derived: sum of 2 quarters · filed 2023-11-07 | $206.19M 10-Q · filed 2023-11-07 | $206.19M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $52.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $196.48M 10-Q · filed 2023-08-07 | $196.48M derived: sum of 3 quarters · filed 2023-08-07 | $201.47M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $143.94M 10-Q · filed 2023-05-04 | $143.94M derived: sum of 2 quarters · filed 2023-05-04 | $148.93M derived: sum of 3 quarters · filed 2023-05-04 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $4.99M derived: sum of 2 quarters · filed 2023-03-06 | $87.23M 10-K · filed 2023-03-06 | |
| 2021-09-30 | $4.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $87.23M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $82.23M 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |